LLY

993.69

-0.41%↓

JNJ

242.55

+0.34%↑

ABBV

226.28

-1.83%↓

NVS

155.7

-3.66%↓

AZN

193.14

-1.88%↓

LLY

993.69

-0.41%↓

JNJ

242.55

+0.34%↑

ABBV

226.28

-1.83%↓

NVS

155.7

-3.66%↓

AZN

193.14

-1.88%↓

LLY

993.69

-0.41%↓

JNJ

242.55

+0.34%↑

ABBV

226.28

-1.83%↓

NVS

155.7

-3.66%↓

AZN

193.14

-1.88%↓

LLY

993.69

-0.41%↓

JNJ

242.55

+0.34%↑

ABBV

226.28

-1.83%↓

NVS

155.7

-3.66%↓

AZN

193.14

-1.88%↓

LLY

993.69

-0.41%↓

JNJ

242.55

+0.34%↑

ABBV

226.28

-1.83%↓

NVS

155.7

-3.66%↓

AZN

193.14

-1.88%↓

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

SectorHealthcare

430.68 -0.41

Buy Sell

Overview

Share price change

24h

Current

Min

425.19

Max

442.79

Key metrics
By Trading Economics
Income	56M -59M
Sales	34M 321M
Profit margin	-18.243
Employees	915
EBITDA	56M -50M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+60.41% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	-716M 9.8B
Previous open	431.09
Previous close	430.68

News Sentiment

By Acuity

100%

330 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 mar 2026, 20:38 UTC

Earnings

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10 mar 2026, 23:57 UTC

Market Talk

Global Equities Roundup: Market Talk

10 mar 2026, 23:57 UTC

Market Talk

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10 mar 2026, 23:47 UTC

Market Talk

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10 mar 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10 mar 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10 mar 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10 mar 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10 mar 2026, 23:35 UTC

Market Talk

Major News Events

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10 mar 2026, 23:06 UTC

Earnings

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10 mar 2026, 22:51 UTC

Major News Events

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10 mar 2026, 21:39 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10 mar 2026, 21:21 UTC

Earnings

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10 mar 2026, 21:15 UTC

Earnings

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10 mar 2026, 21:15 UTC

Acquisitions, Mergers, Takeovers

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10 mar 2026, 21:14 UTC

Earnings

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10 mar 2026, 21:13 UTC

Earnings

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10 mar 2026, 21:12 UTC

Earnings

Franco-Nevada 4Q Rev $597.3M >FNV

10 mar 2026, 21:12 UTC

Earnings

Franco-Nevada 4Q EPS $1.90

10 mar 2026, 20:57 UTC

Earnings

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

10 mar 2026, 20:44 UTC

Earnings

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:34 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

10 mar 2026, 20:34 UTC

Market Talk

Earnings

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10 mar 2026, 20:23 UTC

Earnings

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar 2026, 20:16 UTC

Earnings

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10 mar 2026, 20:14 UTC

Earnings

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10 mar 2026, 20:14 UTC

Earnings

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10 mar 2026, 20:13 UTC

Earnings

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10 mar 2026, 20:12 UTC

Earnings

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

60.41% upside

12 Months Forecast

Average 694.9 USD 60.41%

High 964 USD

Low 529 USD

Based on 11 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

330 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.